Noncanonical Amino Acids Made by Enzymes
Aralez Bio, a San Francisco-based start-up, has engineered a platform of enzymes that creates 100 times more compound diversity using processes that are also 50 times greener than conventional methods.
Innovation
Substitution of Biocides in Cooling Water Treatment
The Heidelberg-based start-up Blue Activity replaces 100% of biocides in cooling water treatment with natural, functional microorganisms. The product change increases the efficiency of cooling tower performance and reduces water consumption and operating costs.
Accelerate Chemical and Material Development
Process manufacturing companies waste almost $100 billion globally every year while formulating novel materials and chemicals due to the trial-and-error approach to R&D and the lack of tools to leverage the experimental data in real-time.
Making Lab Automation Actually Work
Manual experiment monitoring and data capture is still the status quo in most biotech and pharma labs, compromising efficiency and project timescales. But there is a better way.
Accelerating Chemicals Innovation
The Spanish computational chemistry start-up Nextmol (Bytelab Solutions), a spin-off from the Barcelona Supercomputing Centre, offers a software-as-a-service (SaaS) platform that accelerates research and innovation in sustainable specialty chemicals through “in silico” experiments using molecular modeling and artificial intelligence (AI).
Aquamet: Innovative Approach for Sustainable Aquaculture
The Ghanian start-up Aquamet provides a sustainable and affordable solution to maximize fish farmers´ yield.
Traceless, a Game-Changing Biomaterial
In this interview, Christene Smith sits down with Anne Lamp, the CEO & Co-Founder of Traceless Materials, to delve into the groundbreaking world of natural biopolymer materials.
Graphene for Sustainable Development
Interview with Alban Chesneau and Nicolas Castet, Carbon Waters
Fueling the Circular Carbon Economy
Interview with Florian Hildebrand, Greenlyte Carbon Technologies
Silicone Recycling without Loss of Quality
Interview with Klara Yoon, Tina Rose and Stephan Enthaler, New Dawn
Advanced Oxidation Treatment for Wastewater
Interview with Fajer Mushtaq and Silvan Staufert, Oxyle
Axplora Aims to Make Pharmaceutical Supply Chains More Stable
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
Expert Statement: Girish Malhotra, EPCOT International
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Chemistry and the „Next Normal”
Numerous crises such as climate change, energy shortages, raw material shortages, war in Ukraine and the consequences of the pandemic are putting value chains worldwide to the test.
Unlocking Forward-looking Data Analytics Synergies in the Materials Sector
Interview with Lisa Z. Mobech and Bjol R. Frenkenberger, MIR Insight
Bioforsense — From Waste to Value
CH-Bioforce, based in Raisio, Finland, strives for a cleaner world.
Halving Chemical Manufacturing Costs
Traditional batch chemistry is too inefficient for a sustainable future. Switching batch processing to continuous processing is inevitable if the world is to reach net zero.
Sustainable Industrial Wastewater Treatment
For decades, Ferrate(VI) has been known as the strongest oxidant in the world for the treatment of (industrial) wastewater.
Bachem Innovates its Manufacturing Capabilities
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Expert Statement: Jean-Baptiste Guillermin, Axplora
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Stephen D Drake, Kaneka Americas Holdings
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Christophe Girard, Siegfried
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Baburaj Krishnan, Aurigene Pharmaceutical Services
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Mark Muldowney, Sterling Pharma Solutions
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Srividya Ramakrishnan, Dr. Reddy’s Laboratories
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Ulrich Mayerhoeffer, Arxada
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Shawn Walker, Veranova
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Kai Rossen, Euroapi
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
New Covid Shots Score Points against Omicron
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
AI Makes Drug Discovery Faster
Interview with Joachim Haupt and Florian Kaiser, PharmAI
Nanoparticle Engineering
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
